L
Título: Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line
Autores: Wang, Hui-han
Li, Ying-chun
Liao, Ai-jun
Fu, Bei-bei
Yang, Wei
Liu, Zhuo-gang
Wang, Xiao-bin
Fecha: 2011-03-30
Publicador: Chinese Journal of Cancer Research
Fuente: Ver documento
Tipo:
Tema: No aplica
Descripción: Objective: To observe the reversion of multi-drug resistance by proteasome inhibitor bortezomib in K562/DNR cell line and to analyze the possible mechanism of reversion of multidrug-resistance. Methods: MTT method was used to determine the drug resistance of K562/DNR cells and the cellular toxicity of bortezomib. K562/DNR cells were cultured for 12 hours, 24 hours and 36 hours with 100 μg/ml DNR only or plus 4 μg/L bortezomib. The expressions of NF-κB, IκB and P-gp of K562/DNR were detected with Western blot method, the activity of NF-κB was tested by ELISA method and the apoptosis rate was observed in each group respectively. Results: The IC50 of DNR on cells of K562/S and K562/DNR groups were 1.16 μg/ml and 50.43 μg/mL, respectively. The drug-resistant fold was 43.47. The IC10 of PS-341 on Cell strain K562/DNR was 4 μg/L. Therefore, 4 μg/L was selected as the concentration for PS-341 to reverse drug-resistance in this study. DNR induced down-regulation of IκB expression, up-regulation of NF-κB and P-gp expression. After treatment with PS-341, a proteasome inhibitor, the IκB degradation was inhibited, IκB expression increased, NF-κB and P-gp expression decreased in a time dependent manner. Compared to DNR group, the NF-κB p65 activity of DNR+PS-341 group was decreased. Compared to corresponding DNR group, DNR induced apoptosis rate increases after addition of PS-341 in a time dependent manner. Conclusion: Proteasome inhibitor bortezomib can convert the leukemia cell drug resistance. The mechanism may be that bortezomib decreases the degradation of IκB and the expression of NF-κB and P-gp, therefore induces the apoptosis of multi-drug resistant cells.
Idioma: Inglés
Artículos similares:
A Phase II Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China por Yang, Lu,Wang, Zhi-jie,An, Tong-tong,Bai, Hua,Zhao, Jun,Duan, Jian-chun,Li, Ping-ping,Wu, Mei-na,Sun, Hong,Liang, Li,Wang, Jie
Risk Factors And Outcome of Pancreatic Fistula after Consecutive Pancreaticoduodenectomy with Pancreaticojejunostomy for Patients with Malignant Tumor por Zhu, Wei-hua,Li, Shu,Zhang, Da-fang,Peng, Ji-run,Jin, Zhong-tian,Li, Guang-ming,Wang, Fu-shun,Zhu, Ji-ye,Leng, Xi-sheng
Polymorphisms of XPC Gene And Susceptibility of Esophageal Cancer por Feng, Xiang-xian,Duan, Pei-fen,Wang, Li-bing,Lu, Zu-xun
Location of Sentinel Lymph Node in Gastric Cancer: A Modified, Painless And Noninvasive Approach por Su, Xin-hui,Chen, Qiang,Sun, Long,Wu, Hua,Pan, Wei-Ming,Chen, Gui-bing,Luo, Zuo-Ming,Wang, Wei
Low Correspondence of EGFR Mutations in Tumor Tissue And Paired Serum of Non-Small-Cell Lung Cancer Patients por Song, Guo-hong,Ren, Jun,Zhang, Li-jian,Di, Li-jun,Yuan, Yan-hua,Yu, Jing,Jia, Jun
10 
Combined Antitumor Effect of Ursolic Acid And 5-Fluorouracil on Human Esophageal Carcinoma Cell Eca-109 In Vitro por Chen, Guo-qing,Yao, Zhen-wei,Zheng, Wei-ping,Chen, Li,Duan, Hong,Shen, Yi